Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


API 'Well Placed' for Positive Results (Australia)

This article was originally published in PharmAsia News

Executive Summary

Drug distributor Australian Pharmaceuticals Industries posted a net loss of $2.6 million for the past four months. The company maintains despite the negative figures, it is now in a good position to post gains in the near future. The hiccup in profits stems from restructuring API has undertaken during the last year. The company has also worked to improve its interaction with independent pharmacists. Largely, it has focused on Priceline and Priceline Pharmacy assets while addressing some performance concerns in non-core assets. API's efforts have been rewarded. The company became the primary generics supplier for Alphapharm. And in spite of the loss, revenues during the period have actually increased by 7.8 percent to $940.3 million, far more than expected. (Click here for more

You may also be interested in...

China Preps For First COVID Vaccine Roll-Outs

Regulatory pressure to fully approve the first COVID-19 vaccine in China is mounting as top officials tour an inspection agency and two leading manufacturers. 

QUOTED. 3 December. Jessica Schubel.

A proposed rule released last month by the US Department of Health and Human Services is the Trump administration’s “latest attempt to sabotage HHS programs,” wrote Jessica Schubel, a senior policy analyst for the Center on Budget and Policy Priorities. See what the policy expert said about it in her blog post here.

Bukwang Speeds Lead Asset As It Eyes Danish Operation's Listing

Helped by a hefty financing earlier this year, Bukwang subsidiary Contera Pharma is poised to speed ongoing multinational Phase II trials with its lead asset for Parkinson’s-associated dyskinesia by hiring CNS experts as new top executives, as the Korean firm looks to take it public in ground-breaking move.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts